Protalix Biotherapeutics Inc Asset Resilience Ratio
Protalix Biotherapeutics Inc asset resilience ratio. Protalix Biotherapeutics Inc (PLX) has an Asset Resilience Ratio of 36.76% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Protalix Biotherapeutics Inc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Protalix Biotherapeutics Inc (1999–2025)
Asset resilience ratio of Protalix Biotherapeutics Inc from 1999 to 2025. This chart shows how Protalix Biotherapeutics Inc's Asset Resilience Ratio has changed over time. Read debt load of Protalix Biotherapeutics Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Protalix Biotherapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Protalix Biotherapeutics Inc (PLX) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $14.68 Million | 17.83% |
| Short-term Investments | $15.59 Million | 18.94% |
| Total Liquid Assets | $30.27 Million | 36.76% |
Asset Resilience Insights
- Very High Liquidity: Protalix Biotherapeutics Inc maintains exceptional liquid asset reserves at 36.76% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Protalix Biotherapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Protalix Biotherapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Protalix Biotherapeutics Inc Asset Resilience Ratio by Year (1999–2025)
Protalix Biotherapeutics Inc asset resilience ratio by year from 1999 to 2025. The table below shows the annual Asset Resilience Ratio data for Protalix Biotherapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 36.76% | $30.27 Million | $82.35 Million | -10.68pp |
| 2024-12-31 | 47.44% | $34.83 Million | $73.42 Million | -5.33pp |
| 2023-12-31 | 52.77% | $44.56 Million | $84.43 Million | +13.02pp |
| 2022-12-31 | 39.76% | $22.18 Million | $55.79 Million | -16.98pp |
| 2020-12-31 | 56.74% | $38.55 Million | $67.93 Million | +17.49pp |
| 2019-12-31 | 39.25% | $17.82 Million | $45.39 Million | -22.90pp |
| 2018-12-31 | 62.16% | $38.00 Million | $61.13 Million | -9.55pp |
| 2017-12-31 | 71.71% | $51.79 Million | $72.21 Million | +71.13pp |
| 2016-12-31 | 0.58% | $477.00K | $82.25 Million | +0.20pp |
| 2015-12-31 | 0.38% | $371.00K | $97.25 Million | -0.15pp |
| 2014-12-31 | 0.53% | $416.00K | $78.47 Million | +0.21pp |
| 2013-12-31 | 0.32% | $362.00K | $113.33 Million | -0.06pp |
| 2012-12-31 | 0.38% | $298.00K | $78.73 Million | -0.02pp |
| 2011-12-31 | 0.40% | $208.00K | $51.80 Million | +0.05pp |
| 2010-12-31 | 0.35% | $226.00K | $64.73 Million | +0.13pp |
| 2009-12-31 | 0.22% | $213.00K | $98.67 Million | -0.20pp |
| 2008-12-31 | 0.42% | $211.00K | $50.81 Million | +0.34pp |
| 2007-12-31 | 0.07% | $50.00K | $68.14 Million | -0.10pp |
| 2006-12-31 | 0.17% | $47.00K | $26.99 Million | -63.74pp |
| 2000-12-31 | 63.91% | $1.22 Million | $1.90 Million | +12.08pp |
| 1999-12-31 | 51.84% | $1.06 Million | $2.05 Million | -- |
About Protalix Biotherapeutics Inc
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also d… Read more